Platelet-rich Plasma Versus Corticosteroid Injection for the Treatment of Femoroacetabular Impingement

This study will determine if PRP treatment of FAI improves (i) patient reported outcome
scores and (ii) hip functional stability compared to standard corticosteroid treatment and if
PRP treatment of FAI reduces (i) radiographic and (ii) biochemical markers of joint
inflammation and cartilage degradation.

Inclusion Criteria:

- Patients with symptomatic FAI

- Clinical and radiographic evidence of FAI

- Patients able to provide consent to study participation

- Completion of 6 weeks of physical therapy program

Exclusion Criteria:

- Established Osteoarthritis (Kellgren-Lawrence > 3)

- Minimum joint space > 2 mm as measured on AP radiograph

- Hip dysplasia (center edge angle < 20° on AP radiograph)

- Patients with clinically significant cardiovascular, renal, hepatic, endocrine
disease, cancer or diabetes

- Patients with ongoing infection including HIV and Hepatitis

- Patient with history of osteomyelitis/septic arthritis

- Anticoagulation therapy

- Patients who are pregnant or breast feeding

- Patients with systemic, rheumatic or inflammatory disease of the knee or
chondrocalcinosis, hemochromatosis, inflammatory arthritis, arthropathy of the knee
associated with juxta-articular Paget's disease of the femur or tibia, hemophilic
arthropathy, infectious arthritis, Charcot's knee joint, villonodular synovitis, and
synovial chondromatosis

- Patients taking immunosuppressant medication

- Patients with abnormal hematology or serum chemistry lab results

- Patients receiving injection to treatment knee within 2 months of study enrollment

- BMI greater than 35 or less than 20